anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Autosomal dominant polycystic kidney disease (ADPKD) shows a characteristic that kidney function is lost by abnormal proliferation of kidney epithelial cells. Even with the confirmation of gene which causes the ADPKD, effective medicine for the disease has not found so far. The functions of multidrug-resistance associated protein 3 (MRP3) in kidney are merely known. Method: RNAi system and Abcc3 clone for restoration are used to check the functions of the MRP3 in kidney. Fluorescent immunohistochemistry is performed to estimate expression of MRP3 in vivo. Result: MRP3 inhibition by MK571 or siRNA stimulates cell proliferation through ERK/B-Raf signaling pathway. In addition, expression of MRP3 in vivo is confirmed. MRP3 in kidneys of ADPKD patients is down regulated. However, restoration of the MRP3 reduces proliferation and cystogenesis in vitro. Conclusion: Such result tells that the functions of the MRP3 in kidney are related to cell proliferation, and restoration of the MRP3 is effective in polycystic kidney disease treatment.
This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
Patients aged ≥ 18 years with CKD stages 3-4 will be recruited between July 2019 - October 2019. Participants will be randomly allocated into either the intervention (N = 77) or control group (N = 77). The control group will receive standard usual care, while the intervention group will receive standard usual care plus a self-management program delivered by renal nurse educators. The intervention will be guided by social cognitive theory and include group-based educational sessions, CKD booklet and follow-up phone calls. Both groups will be followed for 12 weeks. Data will be analyzed using SPSS version 25. The primary outcomes are improving in knowledge and self-management, while the secondary outcomes are improving in self-confidence, quality of life and clinical outcomes of the participants.
Sustained smouldering, or low-grade activation, of myeloid cells is a common hallmark of several chronic neurological diseases, including multiple sclerosis1. Distinct metabolic and mitochondrial features guide the activation and the diverse functional states of myeloid cells2. However, how these metabolic features act to perpetuate inflammation of the central nervous system is unclear. Here, using a multiomics approach, we identify a molecular signature that sustains the activation of microglia through mitochondrial complex I activity driving reverse electron transport and the production of reactive oxygen species. Mechanistically, blocking complex I in pro-inflammatory microglia protects the central nervous system against neurotoxic damage and improves functional outcomes in an animal disease model in vivo. Complex I activity in microglia is a potential therapeutic target to foster neuroprotection in chronic inflammatory disorders of the central nervous system3.
Systemic corticosteroids, including Budesonide Capsules, may cause a reduction of growth velocity in pediatric patients. Pediatric patients with Crohn’s disease have a 17% higher mean systemic exposure and cortisol suppression than adults with Crohn’s disease [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].

The safety and effectiveness of Budesonide Capsules have not been established in pediatric patients less than 8 years of age.

Pediatric use information is approved for Perrigo Pharma International DAC’s ENTOCORT EC (budesonide) capsules. Additional information describing a clinical study in which efficacy was not demonstrated in patients ages 5 to 17 years for another indication is approved for Perrigo Pharma International DAC’s ENTOCORT EC (budesonide) capsules. However, due to Perrigo Pharma International DAC’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
Complementary DNA encoding a 52 kDa form of a protein present in the human Ro/SSA ribonucleoprotein complex has been cloned. A lambda gt11 cDNA library made from human thymocyte mRNA was screened with serum from a SLE patient and two immunoreactive clones were isolated. These clones reacted with other patient sera which had anti-52 kDa Ro/SSA antibodies and with affinity purified anti-52 kDa Ro/SSA antibodies. Moreover, affinity purified antibodies eluted from fusion proteins of the isolated clones reacted only with the 52 kDa protein of lymphocytes in the Western blot. Ro/SSA RNAs were also precipitated with these affinity purified antibodies, further confirming that the clones encode a 52 kDa Ro/SSA antigen. The sequence differs from the previously reported 60 kDa Ro/SSA gene.
Restoring mobility after spinal cord injury (SCI) is one of the most important goals of rehabilitation. Even for patients with partial lower limb motor function after SCI, many have limited mobility because of significant spasticity. Therapeutic electrical neuromuscular stimulation (TNS) has been used to improve muscle tone and strength and to enable walking and standing in patients with SCI. We propose to use the Radio Frequency Microstimulator (RFM) System, a new and novel implantable TNS system developed by the Alfred E. Mann Foundation, to improve muscle strength and reduce spasticity in a patient with incomplete SCI. The RFM System has several advantages over current TNS systems. The RFM implant devices are small enough (diameter 2.4 mm, length 16.7 mm) to be inserted using an incision approximately 5 mm long and have no lead wires passing through the skin since the microstimulator contains both the anode and cathode. Implanted RFM devices can be placed near multiple motor points and/or nerves and are controlled individually using radio frequency technology. Up to six (6) RFM devices will be inserted, two to three in each lower limb to provide stimulation to a patient's bilateral knee extensors (femoral nerve stimulation) and ankle dorsiflexors (peroneal nerve stimulation) to assess the effects on muscle strength, limb spasticity and patient mobility.
The suggested dosage for androgens varies depending on the age, and diagnosis of the individual patient. Dosage is adjusted according to the patient’s response and the appearance of adverse reactions. The dosage guideline for the testosterone pellets for replacement therapy in androgen-deficient males is 150mg to 450mg subcutaneously every 3 to 6 months. Various dosage regimens have been used to induce pubertal changes in hypogonadal males; some experts have advocated lower doses initially, gradually increasing the dose as puberty progresses, with or without a decrease in maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.

Dosages in delayed puberty generally are in the lower range of that listed above and, for a limited duration, for example 4 to 6 months.

The number of pellets to be implanted depends upon the minimal daily requirements of testosterone propionate determined by a gradual reduction of the amount administered parenterally. The usual dosage is as follows: implant two 75mg pellets for each 25mg testosterone propionate required weekly. Thus when a patient requires injections of 75mg per week, it is usually necessary to implant 450mg (6 pellets). With injections of 50mg per week, implantation of 300mg (4 pellets) may suffice for approximately three months. With lower requirements by injection, correspondingly lower amounts may be implanted. It has been found that approximately one-third of the material is absorbed in the first month, one-fourth in the second month and one-sixth in the third month. Adequate effect of the pellets ordinarily continues for three to four months, sometimes as long as six months.
CircRNAs are abnormally expressed in various cancers and play an important role in the occurrence and development of cancers. However, their biological functions and the underlying molecular mechanisms in pancreatic cancer (PC) metastasis are incompletely understood. Differentially expressed circRNAs were identified by second-generation transcriptome sequencing in three pairs of PC tissues and adjacent tissues. The expression and prognostic significance of hsa_circ_0007919 were evaluated by qRT-PCR and Kaplan-Meier survival curves. Gain- and loss-of-function assays were conducted to detect the role of hsa_circ_0007919 in PC metastasis in vitro. A lung metastasis model and IHC experiments were conducted to confirm the effects of hsa_circ_0007919 on tumor metastasis in vivo. Mechanistically, RNA immunoprecipitation and chromatin immunoprecipitation assays were conducted to explore the interplay among hsa_circ_0007919, Sp1, and the THBS1 promoter. hsa_circ_0007919 was significantly upregulated in PC tissues and cells and was correlated with lymph node metastasis, TNM stage, and poor prognosis. Knockdown of hsa_circ_0007919 significantly suppressed the migration and invasion of PC cells in vitro and inhibited tumor metastasis in vivo. However, overexpression of hsa_circ_0007919 exerted the opposite effects. Mechanistically, hsa_circ_0007919 could recruit the transcription factor Sp1 to inhibit THBS1 transcription, thereby facilitating PC metastasis. hsa_circ_0007919 can promote the metastasis of PC by inhibiting THBS1 expression. hsa_circ_0007919 may be a potential therapeutic target in PC.
In mixts. for coating orthopaedic jaw parts and prosthetic fixing units, e.g. dentures with braces, basic units for cast prostheses patterns, wires, etc., with a synthetic material based on epoxy resins and dyes which approximate to the mucous membrane of the mouth, the synthetic contains a micaceous mineral as filler. ADVANTAGE - The hardening time is shorter by 10-20 mins., and the temp. can be above 100 (120-130) deg.C without formation of blisters. Satisfactory elasticity and hardness can be obtd. The mixt. is more liq. and more easily applied with a brush, and a precise ratio between synthetic and hardener is not necessary.
Subjects randomized to the Telehealth Intervention (TI) group will receive the SC as well as an interactive TI with interactive health education messages via a WhatsApp-based chatbot on the repeat FIT due date. All subjects will be followed up on WhatsApp at 3 months after their repeat FIT due date and asked about their repeat FIT status.
<P>PROBLEM TO BE SOLVED: To provide a method of producing progeny for generally acting to a neural stem cell and a neuronal precursor cell (collectively referred to as "NSC") for substituting a neuron or other cell types of nervous system being damaged, being defective, or being at risk of dying.  <P>SOLUTION: A method for modulating neurogenesis in vitro and in vivo has been disclosed. The methods comprise contacting neural stem cells with an effective amount of a FTY720 compound. The neurogenesis may include the modulation of proliferation, differentiation, migration or survival of a non-embryonic neural stem cells or progenitor cells. There is also provided a method for preventing or treating neurological disorders, including Parkinson's disease, paralysis agitans, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal cord ischaemia, ischemic stroke, spinal cord injury, brain damage associated with cancer, spinal cord injury associated with cancer, and Shy-Drager syndrome, or the like, comprising a step of administering to a subject a therapeutically effective amount of a FTY720 compound.  <P>COPYRIGHT: (C)2011,JPO&INPIT
A method of determining a probability that a patient's blood glucose value is in an adverse range at a prediction time. Spot monitoring blood glucose measurement data is provided and includes blood glucose measurement values and associated measurement times. The values include first and second sets assigned to first and second adverse ranges, respectively. A kernel density estimation and Bayes' rule are used to determine the probability of the blood glucose value of the patient being in the first and second adverse blood glucose ranges at the prediction time. In the kernel density estimation, a first kernel bandwidth is applied for all or some of the first blood glucose measurement values and a second kernel bandwidth different from the first kernel bandwidth is applied for all or some the second blood glucose measurement values. Output data is provided indicative of the prediction time and the probability at the prediction time.
The invention discloses a redissolving self-assembly type poorly-water-soluble drug-polymer micelle composition. The composition comprises poorly-water-soluble drugs and amphiphilic block copolymers in a ratio of 1:19-1:1 by w/w. The invention further discloses a preparation method of the redissolving self-assembly type poorly-water-soluble drug-polymer micelle composition. The preparation method includes firstly, adding the poorly-water-soluble drugs and the amphiphilic block copolymers into organic solvents mutually soluble with water and stirring and mixing uniformly; secondly, mixing the organic solvents with the water or a buffer solution with stirring, filtering an obtained solution from stirring through a microfiltration membrane and drying to obtain the composition, wherein the volume ratio of the organic solvents to the water or the buffer solution is more than or equal to 1 to 3. The prepared composition can be prepared into freeze-dried powder by being added with freeze-drying protective agents, and after redissolving, a drug-loaded solution with grain size ranging from 10nm-100nm can be formed within 20 seconds. The redissolving self-assembly type poorly-water-soluble drug-polymer micelle composition and the preparation method thereof overcome the shortcomings that poorly-water-soluble drug micelle freeze-dried products are difficult to redissolve, low in drug loading capacity after redissolving and non-uniform in grain size distribution.
Bilateral, simultaneous subretinal administration of LUXTURNA was well tolerated at dose levels up to 8.25 x 1010 vg per eye in dogs with a naturally occurring RPE-65 mutation and 7.5 x 1011 vg (5 times higher than the recommended human dose level) per eye in non-human primates (NHPs) with normal-sighted eyes. In both animal models, bilateral, sequential subretinal administrations, where the contralateral eye was injected following the first eye, were well tolerated at the recommended human dose level of 1.5 x 1011 vg per eye. In addition, dogs with the RPE-65 mutation displayed improved visual behavior and pupillary responses. Ocular histopathology showed only mild changes, which were mostly related to healing from the surgical administration procedure. Other findings observed following subretinal injection of LUXTURNA in dogs and NHPs included occasional and isolated inflammatory cells in the retina, with no apparent retinal degeneration. Dogs not previously exposed to AAV2 vectors developed antibodies to the AAV2 capsid following a single administration of LUXTURNA, whereas NHPs did not.
BACKGROUND: Transplantation of mesenchymal stem cells (MSCs) is a newly developed strategy for treating acute liver failure (ALF). Nonetheless, the low survival rate of MSCs after transplantation and their poor homing to damaged tissues limit the clinical application of MSCs. The research assessed whether hypoxic preconditioning (HPC) can improve the biological activity of human amniotic mesenchymal stem cells (hA-MSCs), promote their homing ability to the liver of mice with ALF, and influence liver tissue repair.
METHODS: Flow cytometry, CCK8, Transwell, and Western blotting assays were conducted to assess the effects of hypoxic preconditioning on the phenotype, proliferation, and migration of hA-MSCs and the changes in the c-Met and CXCR4 gene expression levels were studied. To evaluate the effects of the transplantation of hypoxic preconditioning of hA-MSCs on the homing and repair of D-galactosamine (D-GalN)/LPS-induced ALF, the mechanism was elucidated by adding c-Met, CXCR4-specific blockers (SU11274 and AMD3100).
RESULTS: After hypoxia pretreatment (1% oxygen volume fraction), hA-MSCs maintained the morphological characteristics of adherence and vortex colony growth and showed high CD44, CD90, and CD105 and low CD31, CD34, and CD45 expression levels. Hypoxic preconditioning of hA-MSCs significantly increased their proliferation and migration and highly expressed the c-Met and CXCR4 genes. In vivo and in vitro, this migration-promoting effect was suppressed by the c-Met specific blocker SU11274. In the acute liver failure mouse model, the HGF expression level was considerably elevated in the liver than that in the serum, lungs and kidneys. The transplantation of hypoxic preconditioned hA-MSCs introduced a remarkable improvement in the liver function and survival rate of mice with ALF and enhanced the anti-apoptosis ability of liver cells. The anti-apoptotic enhancing effect of hypoxic preconditioning was suppressed by the c-Met specific blocker SU11274. Hypoxic hA-MSCs administration was observed to have considerably increased the fluorescent cells in the liver than that recorded after administering normal oxygen-hA-MSCs. The number of hepatic fluorescent cells decreased remarkably after adding the c-Met inhibitor SU11274, compared to that recorded after hypoxic pretreatment, whereas the effect of c-Met inhibitor SU11274 on normal oxygen-hA-MSCs was not significant.
CONCLUSIONS: Hypoxic preconditioning depicted no impact on the morphology and phenotype features of the human amniotic mesenchymal stem cells, but it can promote their proliferation, migration, anti-apoptotic effect, and homing rate and improve the repair of acute liver failure, which might be mediated by the HGF/c-Met signaling axis.
An orthodontic bracket includes a protective coating material on the bracket surface to increase resistance to wear and deformation and/or to improve surface properties. The coating layer includes a cured resin chemically bonded to or crosslinked with a plurality of organically modified inorganic particles. The protective coating layer makes the surface of the bracket very hard and resistant to abrasion. The entire bracket, or any portion thereof, can be coated. For example, the arch wire slot and/or ligation cover can be coated since these portions of the bracket typically receive the greatest mechanical stress and/or abrasion. The coating material can be applied in very thin layers such as less than 10 microns, thereby minimizing the effect that the coating has on the overall shape and size of the orthodontic bracket.
Angiogenesis, the formation of new blood vessels, stimulates tumor growth and spread by delivering oxygen and nutrients, and is a key component of metastasis. This work aimed to evaluate the anti-angiogenic properties of a new synthesized compound. Rat aorta angiogenesis assay was used to evaluate the ability of the carbothioamide derivative to inhibit blood vessels sprouting. The tetrazolium (MTT) assay was used to evaluate the anti-proliferative effect of the synthetic compound on human umbilical vein endothelial cell line (HUVECs) and A549 lung cancer cells line. The (2, 2-diphenyl-1-picrylhydrazyl) DPPH was used to investigate the free radical scavenging action. The study showed that the compound has anti-angiogenic activity with IC50 56.9 µg/mL, moreover the compound managed to inhibit the proliferation of HUVECs and A549 cells (IC50 76.3 µg/mL and 45.5 µg/mL, respectively), and The IC50 concentration for free radical scavenging activity of the compound was 27.8 µg/ml. The study concluded that the compound has significant anti-angiogenic activity may be related to its significant anti-proliferative effect against HUVECs, these pharmacological effect may attributed to its potent free radical scavenging activity.
FIELD: medicine. SUBSTANCE: rheapherone is applied to patients rectally together with commonly used non-steroid and hormonal preparations. Dose of rheapherone is 70-100000 units per 1 kg of body mass (daily dose being not more 2 million units). Said preparation is used at 12 hourly intervals within 10-12 days. Further preparation is used 3 times a week within 5-6 months. Simultaneously α-tocopherol and ascorbic acid are applied at age dose, the former preparation being injected rectally, the latter one intramuscularly. EFFECT: decreases activity of the disease, prevents complications of medicinal therapy. 1 tbl
There is currently very limited information on the nature and prevalence of post-COVID-19 symptoms after hospital discharge. On 11th March 2020, corona virus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organisation (WHO). Egypt has been one of the worst affected countries with over 101,500 confirmed cases and more than 5,696 confirmed deaths at the time of writing (17/9 2020) .1 COVID-19 is caused by the corona virus SARSCoV-2 and presents with a wide spectrum of clinical symptoms. Wu et al reported that 81% of people with COVID-19 in China presented with mild symptoms; 14% presented with symptoms of severe respiratory dysfunction; and 5% developed a critical illness with respiratory failure, septic shock, and multiple organ dysfunction or failure.2 The medium and long-term problems experienced by survivors of COVID-19 after discharge from hospital are currently unknown, but there is some emerging evidence. An Italian study followed-up 143 individuals 7 weeks post-discharge and found 53% reporting fatigue, 43% breathlessness and 27% joint pain.3 Post-discharge symptoms may also be predicted from the previous coronavirus outbreaks of Severe Acute Respiratory Syndrome (SARS) in 2002 and Middle East Respiratory Syndrome (MERS) in 2012. A meta-analysis of 28 follow-up studies found that one quarter of hospitalised survivors of SARS and MERS had reduced lung function and exercise capacity at six months post-discharge.4 At one year, post-traumatic stress disorder (PTSD), depression and anxiety, and reduced quality of life were observed Specific data concerning the rehabilitation needs of this group is therefore urgently required.